CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Invex Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Invex Therapeutics Ltd
Level 2, 38 Rowland St, Subiaco
PERTH, WAS  6008  Australia Ticker: IXCIXC
Business Summary
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP) including traumatic brain injury (TBI), stroke and hydrocephalus. In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Presendin is the Company’s filed (and granted) trademark name for reformulated Exenatide. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20246/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Non-Executive Chairman of the Board DavidMcauliffe 7/10/2023 3/8/2019
Chief Financial Officer, Company Secretary NarelleWarren 1/1/2022 3/8/2019
Chief Operating Officer CarolParish 7/1/2022 7/1/2022
Executive Director ThomasDuthy 1/1/2022 10/1/2020
Non-Executive Director David C.Wheeler 11/8/2023 11/8/2023

General Information
Outstanding Shares: 75,153,848 (As of 6/30/2024)
Shareholders: 1,141
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024